WO2007103288A3 - Engineered antibody drug conjugates - Google Patents

Engineered antibody drug conjugates Download PDF

Info

Publication number
WO2007103288A3
WO2007103288A3 PCT/US2007/005552 US2007005552W WO2007103288A3 WO 2007103288 A3 WO2007103288 A3 WO 2007103288A3 US 2007005552 W US2007005552 W US 2007005552W WO 2007103288 A3 WO2007103288 A3 WO 2007103288A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug conjugates
antibody drug
engineered antibody
ligand drug
drugs
Prior art date
Application number
PCT/US2007/005552
Other languages
French (fr)
Other versions
WO2007103288A2 (en
Inventor
Charlotte Mcdonagh
Paul Carter
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of WO2007103288A2 publication Critical patent/WO2007103288A2/en
Publication of WO2007103288A3 publication Critical patent/WO2007103288A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides ligand drug conjugates for targeted delivery of drugs. The ligand drug conjugates have potent cytotoxic activity against antigen-specific targets, as compared with intact antibody drug conjugates.
PCT/US2007/005552 2006-03-02 2007-03-02 Engineered antibody drug conjugates WO2007103288A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77847206P 2006-03-02 2006-03-02
US60/778,472 2006-03-02
US87234806P 2006-12-01 2006-12-01
US60/872,348 2006-12-01

Publications (2)

Publication Number Publication Date
WO2007103288A2 WO2007103288A2 (en) 2007-09-13
WO2007103288A3 true WO2007103288A3 (en) 2007-11-29

Family

ID=38475456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005552 WO2007103288A2 (en) 2006-03-02 2007-03-02 Engineered antibody drug conjugates

Country Status (1)

Country Link
WO (1) WO2007103288A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
JP7458997B2 (en) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー Modified self-cleaving moieties for use in prodrugs and conjugates and methods of use and preparation thereof

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2609915T3 (en) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 addressed to the EGF receptor and derivatives and uses thereof
US7968687B2 (en) * 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
WO2009059309A2 (en) * 2007-11-01 2009-05-07 Panacea Pharmaceuticals, Inc. Furin-cleavable peptide linkers for drug-ligand conjugates
ES2669591T3 (en) 2008-06-20 2018-05-28 Novartis Ag Immunoglobulins with reduced aggregation
AU2009259906B2 (en) 2008-06-20 2016-06-16 Massachusetts Institute Of Technology Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
PL2326350T3 (en) 2008-09-08 2014-03-31 Psma Dev Company L L C Compounds for killing psma-expressing, taxane-resistant cancer cells
ES2537566T3 (en) 2009-06-04 2015-06-09 Novartis Ag Methods for site identification for IgG conjugation
WO2011038159A2 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
TWI689314B (en) 2010-11-30 2020-04-01 建南德克公司 Low affinity blood brain barrier receptor antibodies and uses therefor
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
KR101972303B1 (en) 2011-06-10 2019-04-25 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
SG11201504887TA (en) 2012-12-21 2015-07-30 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
JP6431038B2 (en) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド Cytotoxic and antimitotic compounds and methods of use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
ES2754397T3 (en) 2013-10-11 2020-04-17 Asana Biosciences Llc Protein-polymer-drug conjugates
MX367851B (en) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates.
CA2921707C (en) 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
PL3082877T3 (en) 2013-12-17 2020-02-28 Novartis Ag Cytotoxic peptides and conjugates thereof
AU2014373593B2 (en) * 2013-12-23 2020-07-16 Zymeworks Bc Inc. Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
KR102384740B1 (en) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 Sulfonamide-containing linkage systems for drug conjugates
WO2015113476A1 (en) * 2014-01-29 2015-08-06 上海恒瑞医药有限公司 Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
MX2016016515A (en) 2014-06-13 2017-04-27 Novartis Ag Auristatin derivatives and conjugates thereof.
MX2016016490A (en) 2014-06-20 2017-07-28 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof.
CN106661123A (en) * 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 Anti-Cd22 Antibody-Drug Conjugates And Methods Of Using Thereof
HUE057768T2 (en) 2014-09-17 2022-06-28 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
TWI753875B (en) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 Tetravalent anti-psgl-1 antibodies and uses thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP7023933B2 (en) * 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー Seco-cyclopropyrroloindole compound, its antibody-drug conjugate, and how to make and use it.
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
MX2019007019A (en) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43.
IL269398B2 (en) 2017-03-24 2024-05-01 Seagen Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN113227127A (en) 2018-06-05 2021-08-06 伦敦大学国王学院 Delivering payload to gastrointestinal System BTNL3/8 targeting construct
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006446A2 (en) * 1997-07-30 1999-02-11 Fuchsbauer Hans Lothar Method for transglutaminase-catalyzed coupling of protein or peptide to a support
US20040052793A1 (en) * 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006446A2 (en) * 1997-07-30 1999-02-11 Fuchsbauer Hans Lothar Method for transglutaminase-catalyzed coupling of protein or peptide to a support
US20040052793A1 (en) * 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUTHERLAND ET AL.: "Lysosomal Trafficking Cysteine Protease Metabolism Confer Targe-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 15, 16 February 2006 (2006-02-16), pages 10540 - 10547, XP055009569, DOI: doi:10.1074/jbc.M510026200 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
JP7458997B2 (en) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー Modified self-cleaving moieties for use in prodrugs and conjugates and methods of use and preparation thereof

Also Published As

Publication number Publication date
WO2007103288A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2007103288A3 (en) Engineered antibody drug conjugates
WO2007137170A3 (en) Anti-glypican-3 antibody drug conjugates
HK1190909A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
WO2008112873A3 (en) Binding ligand linked drug delivery conjugates of tubulysins
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
WO2007130491A3 (en) Patient customized therapeutic regimens
IL231322A0 (en) Intraocular drug delivery systems
SI2308514T1 (en) Conjugates for targeted drug delivery across the blood-brain barrier
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
WO2007150030A3 (en) Microfluidic synthesis of organic nanoparticles
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2009137378A3 (en) Sequential administration of chemotherapeutic agents for treatment of cancer
WO2008120207A3 (en) Compositions for nasal delivery
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2008112288A3 (en) Oligomer-opioid agonist conjugates
EP1998751A4 (en) Devices, systems and methods for medicament delivery
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2009087634A3 (en) Methods and compositions for oral administration of insulin
WO2007001888A3 (en) New regimens for controlled drug delivery devices for contraception
LTPA2019508I1 (en) Drug delivery system for the delivery of hard-water-soluble, pharmaceutically active substances
MX2010005813A (en) Oligomer-tricyclic conjugates.
WO2009005718A8 (en) Polypeptide microparticles having sustained release characteristics, methods and uses
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07752266

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07752266

Country of ref document: EP

Kind code of ref document: A2